Efficacy and Safety of Angelica Gigas N. Extract on Improvement of Hyperglycemia

This study was a 8 weeks, randomized, double-blind, placebo-controlled 2×2 cross-over design human trial. Twenty subjects were randomly divided into Angelica gigas N. extract or a placebo group. Fasting and postprandial glucose profiles during oral glucose tolerance test (OGTT) were assessed before and after the intervention.

Inclusion criteria

• Age 20-80 years with fasting glucose 100-125 mg/dL or 2 hour postprandial glucose 140-199 mg/dl

Exclusion criteria

• Weight less than 48 kg or weight decreased by more than 10% within past 3 months
• Hypoglycemic agent, Obesity medicine, Lipid lowering agent within past 6 months or Blood sugar, Obesity and Lipid improvement functional foods within past 2 weeks
• Treated with corticosteroid within past 4 weeks
• Severe cardiovascular disease(Mvocardial infarction, Stroke, etc)
• Renal disease(Heredity hyperlipidemia, Acute/Chronic renal failure, Nephrotic syndrome, etc)
• Rheumatoid arthritis, Autoimmune disease
• Cancer, Respiratory organ disease(Asthma, Chronic obstructive pulmonary disease)
• Allergic or hypersensitive to any of the ingredients in the test products
• History of disease that could interfere with the test products or impede their absorption
• Under antipsychotic drugs therapy within past 2 months
• History of alcohol or substance abuse
• Participation in any other clinical trials within past 2 months
• Laboratory test by show the following results

• aspartate aminotransferase, alanine aminotransferase > Reference range upper limit treble
• Serum Creatinine > 2.0 mg/dl
• Pregnancy or breast feeding
• Not Contraception(except: Surgery for female infertility)